Program
elecoglipron
Also written as “Elecoglipron”, “AZD5004” and “ECC5004”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Heart Failure · Renal Insufficiency, Chronic · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 2211 open or running | phase 3since Jun 18, 2026 | Aug 13, 2024 | Nov 18, 2026phase 1 · NCT07723833 |
| Eccogene | 40 open or running | phase 1since Dec 8, 2022 | Dec 8, 2022 | none ahead |
- Named in AstraZeneca’s own pipeline as
elecoglipron
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel and quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Dec 8, 2022.
- Aug 28, 20242 phase 2 studiesAstraZeneca · NCT06579105, NCT06579092
- Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT06703658 · 35 enrolled · Japan
- Dec 16, 20242 phase 1 studiesAstraZeneca · NCT06742762, NCT06813781
- Feb 27, 2025Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06857695 · 8 enrolled · United Kingdom
- Apr 28, 2025Phase 1 study in ObesityAstraZeneca · NCT06948747 · 49 enrolled · United States
- May 16, 2025Phase 1 study in ObesityEccogene · NCT06988553 · 45 enrolled · China
- May 21, 2025Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT06996886 · 16 enrolled · United States
- Feb 26, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07444424 · 32 enrolled · Japan
- Mar 3, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07455825 · 65 enrolled · United States
- Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592 · 48 enrolled · United States
- Jun 18, 20266 phase 3 studiesPhase 3 reachedAstraZeneca · NCT07664553, NCT07662213, NCT07662135 and 3 more
- Jul 20, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07723833 · 152 planned · United States
- Aug 3, 20263 phase 3 studiesAstraZeneca · NCT07761117, NCT07753993, NCT07775404
- Oct 1, 2026Primary completion moved from 2027-06-04 to 2028-04-06Date moved laterphase 3 · +10 months · NCT07775404
Ahead
- Nov 18, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07723833
- Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592
- Apr 6, 2028Primary completion: phase 3 study in ObesityAstraZeneca · NCT07775404
- May 23, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07664553
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07775404Obesity · China, Hong Kong, Malaysia and more | 3 | Recruiting | AstraZeneca | Apr 6, 2028 | 351 |
| NCT07753993Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Oct 4, 2030 | 7,000 |
| NCT07761117Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Sep 3, 2029 | 6,950 |
| NCT07723833Diabetes Mellitus, Type 2 · United States | 1 | Recruiting | AstraZeneca | Nov 18, 2026 | 152 |
| NCT07667803Weight Management · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Jul 31, 2028 | 4,500 |
| NCT07664553Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more | 3 | Recruiting | AstraZeneca | May 23, 2028 | 600 |
| NCT07662213Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | May 23, 2028 | 1,200 |
| NCT07662135Diabetes Mellitus, Type 2 · United States, Bulgaria, China and more | 3 | Recruiting | AstraZeneca | Jul 13, 2028 | 900 |
| NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | AstraZeneca | Jul 5, 2028 | 2,000 |
| NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Recruiting | AstraZeneca | Jul 14, 2028 | 800 |
| NCT07534592Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | AstraZeneca | Jan 25, 2027 | 48 |
| NCT07455825Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Jun 1, 2026 | 65 |
| NCT07444424Diabetes Mellitus, Type 2 · Japan | 1 | Completed | AstraZeneca | Jul 2, 2026 | 32 |
| NCT06996886Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Jul 15, 2025 | 16 |
| NCT06988553Obesity · China | 1 | Completed | Eccogene | Nov 28, 2025 | 45 |
| NCT06948747Obesity · United States | 1 | Completed | AstraZeneca | Oct 3, 2025 | 49 |
| NCT06857695Healthy Participants · United Kingdom | 1 | Completed | AstraZeneca | May 5, 2025 | 8 |
| NCT06813781Hepatic Impairment · United States | 1 | Completed | AstraZeneca | Oct 2, 2025 | 33 |
| NCT06742762Renal Insufficiency · United States | 1 | Completed | AstraZeneca | Apr 20, 2025 | 16 |
| NCT06703658Diabetes Mellitus, Type 2 · Japan | 1 | Completed | AstraZeneca | Mar 13, 2025 | 35 |
| NCT06579105Diabetes Mellitus, Type 2 · United States, Canada, Germany and more | 2 | Completed | AstraZeneca | Dec 19, 2025 | 406 |
| NCT06579092Obesity · United States, Australia, Canada and more | 2 | Completed | AstraZeneca | Nov 21, 2025 | 310 |
| NCT06555822Obesity · United States | 1 | Completed | AstraZeneca | Mar 6, 2025 | 31 |
| NCT06293742Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eccogene | Apr 15, 2024 | 48 |
| NCT06268145Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eccogene | Mar 29, 2024 | 14 |
| NCT05654831Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eccogene | Nov 1, 2023 | 69 |
How it is read
Names in the registry
- “Elecoglipron”, 10 entries
- “AZD5004”, 10 entries
- “ECC5004”, 3 entries
- “Elecoglipron Reference Formulation Dose A”, 1 entry
- “Elecoglipron Reference Formulation Dose B”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Obesity, 5 studies
- Heart Failure, 1 study
- Renal Insufficiency, Chronic, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.